The benefit of chemotherapy is expressed as a percentage based on the likelihood of distant recurrence with and without chemotherapy. Chemotherapy benefit is considered "none" if the absolute benefit is <1%.

Node-negative patients (NO): Analyses from the TAILORx study by age demonstrated that patients aged ≤50 years achieved clinically significant chemotherapy benefit at 9 years starting with an RS® result of 16.

Node-positive patients (N1): Data from the RxPONDER study were analyzed according to menopausal status and demonstrated that premenopausal patients with RS® results of 0 to 25 generally benefited from chemotherapy within 5 years.

*Chemotherapy benefit for premenopausal N1 patients with RS® results of 26 to 100 has not been formally evaluated in a randomized study. Chemotherapy benefit was significant for RS results of 0 to 13 and 14 to 25 in the RxPONDER study, and it is assumed that the benefit is substantial for patients with RS results of 26 to 100.